Method for separating and culturing hematopoietic stem cells from umbilical cord blood

By combining sodium selenite and phosphoryl dipeptide with hydroxyethyl starch precipitation, hematopoietic stem cells are efficiently isolated from umbilical cord blood, solving the problem of low recovery and removal rates in the prior art, and achieving high-quality hematopoietic stem cell preparation , improves the therapeutic effect.

CN119060953AActive Publication Date: 2024-12-03SHANGHAI YUANSHENGKE PHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411252678.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-06
Publication Date
2024-12-03
Estimated Expiration
2044-09-06

AI Technical Summary

Technical Problem

In the prior art, the recovery rate and red blood cell removal rate of hematopoietic stem cells isolated from umbilical cord blood are relatively low, which affects the therapeutic effect.

Method used

Hydroxyethyl starch (HES) precipitation method combined with sodium selenite and phosphoryl dipeptide, mixed hydroxyethyl starch solution and umbilical cord blood, centrifugation was performed to collect white blood cells rich in plasma and remove plasma, thereby improving the recovery rate of hematopoietic stem cells. and purity.

Benefits of technology

It significantly improves the recovery rate of hematopoietic stem cells and the removal rate of red blood cells, ensures high-quality isolation and culture of hematopoietic stem cells, and enhances cell viability and amplification capabilities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a method for separating and culturing umbilical cord blood-derived hematopoietic stem cells, which comprises the step of preparing hematopoietic stem cells by using a hydroxyethyl starch (HES) precipitation method, and the used hydroxyethyl starch solution contains sodium selenite and phosphoryl dipeptide. The recovery rate of the hematopoietic stem cells obtained by the method is increased, and the removal rate of red blood cells is also increased.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of hematopoietic stem cell preparation, and in particular to a method for separating and culturing umbilical cord blood stem cells from umbilical cord blood. Background Art

[0002] As multipotent stem cells, hematopoietic stem cells continuously replenish red blood cells, white blood cells and platelets in the blood. Hematopoietic stem cells have a high degree of self-renewal or self-replication ability to maintain the number of stem cells at a certain level; at the same time, hematopoietic stem cells can further differentiate into progenitor cells and mature blood cells. Hematopoietic stem cells are usually divided into CD34 + Cell populations and CD34 - Cell population, among which CD34 + The cell population accounted for more than 95%, and CD34 - Therefore, when we refer to hematopoietic stem cells, we usually refer to CD34 + Cell population.

[0003] Hematopoietic stem cells come from a variety of sources, among which umbilical cord blood hematopoietic stem cells are a type of umbilical cord blood that has the ability to differentiate, self-renew and proliferate. Moreover, umbilical cord blood hematopoietic stem cells can be specialized into various cells or tissues under the influence or induction of specific factors. In the medical field, umbilical cord blood hematopoietic stem cell transplantation can repair the subject's hematopoietic function and enhance its immune function. At present, umbilical cord blood hematopoietic stem cells have been widely used in the treatment of leukemia, autoimmune diseases, etc.

[0004] How to prepare high-quality hematopoietic stem cells from umbilical cord blood is a key factor in the effectiveness of hematopoietic stem cell therapy. So far, many countries and regions have built umbilical cord blood banks that meet the standards. In the prior art, the separation of hematopoietic stem cells from umbilical cord blood usually has the problems of low recovery rate and low red blood cell removal rate. Summary of the invention

[0005] The present inventors have overcome the above-mentioned shortcomings through in-depth research and provided a novel method for separating and culturing hematopoietic stem cells from umbilical cord blood, which is simple to operate, has a high yield and high purity.

[0006] Specifically, in the first aspect, the present invention provides a novel method for preparing hematopoietic stem cells, characterized in that the method comprises preparing hematopoietic stem cells using a hydroxyethyl starch (HES) precipitation method, wherein the hydroxyethyl starch solution used contains sodium selenite and phosphoramidon.

[0007] The method for preparing hematopoietic stem cells of the present invention comprises mixing a hydroxyethyl starch solution with umbilical cord blood, centrifuging to collect plasma rich in leukocytes, and centrifuging again to remove the plasma.

[0008] The novel method for preparing hematopoietic stem cells of the present invention further comprises the following steps:

[0009] a. Obtain cryopreserved and resuscitated umbilical cord blood;

[0010] b. preparing a hydroxyethyl starch solution and adding sodium selenite and phosphoryl dipeptide to the solution;

[0011] c. Mixing the hydroxyethyl starch solution added with sodium selenite and phospho-dipeptide with the umbilical cord blood;

[0012] d. Centrifuge and collect leukocyte-rich plasma;

[0013] e. Centrifuge a second time to remove plasma.

[0014] In an embodiment of the present invention, the concentration of sodium selenite is 1 to 100 μM: the concentration of the phosphoryl dipeptide is 0.1 to 50 μM. Exemplarily, the concentration of sodium selenite is 10 to 50 μM, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, the concentration of the phosphodiester is 0.5 to 30 μM, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 μM.

[0015] Further preferably, the concentration of the sodium selenite is 10 to 20 μM, and the concentration of the phosphoryl dipeptide is 2 to 10 μM. Exemplarily, when the concentration of the sodium selenite is 10 to 20 μM, the concentration of the phosphoryl dipeptide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 μM. Alternatively, when the concentration of the phosphoryl dipeptide is 2 to 10 μM, the concentration of the sodium selenite is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 μM. The concentrations of the sodium selenite and the phosphoryl dipeptide can be arbitrarily combined, for example, the concentration of the sodium selenite is 10 μM, and the concentration of the phosphoryl dipeptide is 2 μM; or, the concentration of the sodium selenite is 20 μM, and the concentration of the phosphoryl dipeptide is 10 μM.

[0016] Furthermore, the concentration of the hydroxyethyl starch solution is 6%.

[0017] The ratio of the hydroxyethyl starch solution to the umbilical cord blood is 1:4 to 1:6, preferably 1:5.

[0018] In step a, the umbilical cord blood comes from an umbilical cord blood bank, or can be from umbilical cord blood in a collection bag within 12 hours of collection time.

[0019] In step b, after adding sodium selenite and phosphoryl dipeptide to the hydroxyethyl starch solution, the sodium selenite, phosphoryl dipeptide and hydroxyethyl starch solution should be fully mixed.

[0020] In step c, the hydroxyethyl starch solution is mixed with the umbilical cord blood by shaking or hand-held, for example, by shaking on a shaker for 5-10 minutes or by hand-held inversion.

[0021] In step d, the centrifugation is the first centrifugation, and the centrifugation temperature is lower than 15°C, for example, centrifugation is performed at 5-15°C, 40-60g, and the centrifugation time is 5-10 minutes.

[0022] In step e, the centrifugation is a second centrifugation, and the centrifugation temperature is lower than 15°C, for example, centrifugation is performed at 5-15°C, 300-500g, and the centrifugation time is 5-10 minutes.

[0023] Optionally, mononuclear cells separated from umbilical cord blood are subjected to adherent culture to allow the mononuclear cells to expand, and then subjected to adherent purification, i.e., purified hematopoietic stem cells.

[0024] The method for preparing hematopoietic stem cells adopted in the present invention has good compliance for the subject, because, compared with other approaches, the method of the present invention will not cause any damage to the body of the subject.

[0025] Current research has found that hematopoietic stem cells isolated from umbilical cord blood samples have better vitality. Moreover, if a lot of umbilical cord blood is not collected, it will be discarded. Therefore, isolating hematopoietic stem cells from umbilical cord blood is also a desirable way to turn waste into treasure.

[0026] In a second aspect, the present invention also provides a hematopoietic stem cell, which is prepared by the separation method of the present invention.

[0027] Optionally, the stem cells are hematopoietic stem cells prepared by separation and further expanded and cultured in vitro and purified.

[0028] In a third aspect, the present invention provides the use of sodium selenite and / or phosphoryl dipeptide in preparing a kit for separating hematopoietic stem cells from umbilical cord blood.

[0029] Illustratively, the present invention provides the use of sodium selenite in preparing a kit for isolating hematopoietic stem cells from umbilical cord blood.

[0030] Furthermore, the present invention provides the use of the phosphoryl dipeptide in preparing a kit for separating hematopoietic stem cells from umbilical cord blood.

[0031] Alternatively, the present invention provides a use of a combination of sodium selenite and phosphoryl dipeptide in preparing a kit for separating hematopoietic stem cells from umbilical cord blood.

[0032] Exemplarily, the present invention further provides a kit comprising sodium selenite and phosphoryl dipeptide provided in combination, wherein the ratio (mass) of sodium selenite to phosphoryl dipeptide can be: about 1:0.01 to about 1:99, preferably about 1:1, about 1:1.5, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90 and the ratio range between the ratios; or about 0.1:1 to about 100:1, for example, about 0.1:1, about 0.2 :1, about 0.3:1, about 0.4:1, about 0.45:1, about 0.5:1, about 0.55:1, about 0.6:1, about 0.65:1, about 0.7:1, about 0.75:1, about 0.8:1, about 0.85:1, about 0.9:1, about 0.95:1, about 1:1, about 1:1.1, about 1.2:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, and ranges of ratios between the above ratios.

[0033] Further, the present invention also provides a kit, which comprises sodium selenite and phosphoryl dipeptide provided separately, wherein the ratio (mass) of sodium selenite to phosphoryl dipeptide can be: about 1:0.01 to about 1:99, preferably about 1:1, about 1:1.5, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90 and the ratio range between the said ratios; or about 0.1:1 to about 100:1, for example, about 0.1:1, about 0.2 :1, about 0.3:1, about 0.4:1, about 0.45:1, about 0.5:1, about 0.55:1, about 0.6:1, about 0.65:1, about 0.7:1, about 0.75:1, about 0.8:1, about 0.85:1, about 0.9:1, about 0.95:1, about 1:1, about 1:1.1, about 1.2:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, and ranges of ratios between the above ratios.

[0034] In a fourth aspect, the present invention provides a hydroxyethyl starch solution containing sodium selenite and phosphoryl dipeptide.

[0035] In an embodiment of the present invention, the concentration of sodium selenite is 1 to 100 μM: the concentration of the phosphoryl dipeptide is 0.1 to 50 μM. Exemplarily, the concentration of sodium selenite is 10 to 50 μM, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, the concentration of the phosphodiester is 0.5 to 30 μM, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 μM.

[0036] Further preferably, the concentration of the sodium selenite is 10 to 20 μM, and the concentration of the phosphoryl dipeptide is 2 to 10 μM. Exemplarily, when the concentration of the sodium selenite is 10 to 20 μM, the concentration of the phosphoryl dipeptide is 2, 3, 4, 5, 6, 7, 8, 9, or 10 μM. Alternatively, when the concentration of the phosphoryl dipeptide is 2 to 10 μM, the concentration of the sodium selenite is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 μM. The concentrations of the sodium selenite and the phosphoryl dipeptide can be arbitrarily combined, for example, the concentration of the sodium selenite is 10 μM, and the concentration of the phosphoryl dipeptide is 2 μM; or, the concentration of the sodium selenite is 20 μM, and the concentration of the phosphoryl dipeptide is 10 μM.

[0037] Furthermore, the concentration of the hydroxyethyl starch solution is 6%.

[0038] In a fifth aspect, the present invention also provides a composition comprising sodium selenite and phosphoryl dipeptide.

[0039] Exemplarily, the ratio (mass) of sodium selenite to phosphoryl dipeptide can be: about 1:0.01 to about 1:99, preferably about 1:1, about 1:1.5, about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 1:20, about 1:30, about 1:40, about 1:50, about 1:60, about 1:70, about 1:80, about 1:90 and the ratio range between the said ratios; or about 0.1:1 to about 100:1, for example, about 0.1:1, about 0.2:1, about 0.3:1, about 0.4:1, about 0.5:1, about 0.6:1, about 0.7:1, about 0.8:1, about 0.9:1, about 10:10, about 11:11, about 12:13, about 13:14, about 14:15 about 0.45:1, about 0.5:1, about 0.55:1, about 0.6:1, about 0.65:1, about 0.7:1, about 0.75:1, about 0.8:1, about 0.85:1, about 0.9:1, about 0.95:1, about 1:1, about 1:1.1, about 1.2:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 20:1, about 30:1, about 40:1, about 50:1, about 60:1, about 70:1, about 80:1, about 90:1, and ranges of ratios between the above ratios.

[0040] In a sixth aspect, the present invention provides use of hematopoietic stem cells separated or cultured by the method of the present invention in treating leukemia or immune diseases.

[0041] In a specific embodiment, the leukemia includes acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, mixed cell leukemia, etc.

[0042] Immune diseases refer to pathological reactions caused by damage to the immune system. For example, infectious diseases, hypersensitivity diseases, autoimmune diseases, immunoproliferative diseases, immunodeficiency diseases and immune-related diseases. Exemplarily, the immune diseases are lupus erythematosus, ankylosing spondylitis, rheumatoid arthritis, psoriasis, erythroderma, glomerulonephritis, Anka-associated vasculitis, scleroderma, primary systemic amyloidosis, autoimmune hepatitis, autoimmune pancreatitis, autoimmune gastritis, Crohn's disease, ulcerative colitis, erythema nodosum, thyroiditis, alopecia areata, and related diabetes.

[0043] The hematopoietic stem cell population of the present invention can be formulated and administered as a pharmaceutical composition. Exemplarily, the pharmaceutical composition is any form known in the medical field, such as an injection (e.g., an injection, a lyophilized powder). In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solution (e.g., an isotonic saline solution or a physiological saline solution), a dispersion, a suspension, or an emulsion.

[0044] In a seventh aspect, the present invention provides a drug for treating leukemia or immune diseases, which comprises hematopoietic stem cells separated or cultured by the method of the present invention.

[0045] Exemplarily, the growth curve of the isolated hematopoietic stem cells is measured by WST method, MTT method, ATP detection method, DNA content detection method, etc. to evaluate the growth activity of umbilical cord hematopoietic stem cells. In addition, the isolated and cultured umbilical cord hematopoietic stem cells can be identified by detecting cell surface markers by flow cytometry and detecting cell expression genes by PCR.

[0046] In an eighth aspect, the present invention provides a pharmaceutical composition comprising the hematopoietic stem cells isolated or cultured according to the present invention. In certain embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient, or other auxiliary materials that may be required.

[0047] In this article, the term "excipient" refers to a substance other than the active ingredient (hematopoietic stem cell) that is necessary for the preparation or formulation of a pharmaceutical preparation. Generally speaking, these substances have no physiological activity and do not affect the efficacy and content determination of the drug in the pharmaceutical preparation, nor the stability of the pharmaceutical composition. The main purpose of adding an excipient is to facilitate the preparation of the pharmaceutical composition and facilitate clinical application. Preferably, the excipient used in the pharmaceutical composition of the present invention is medicinal and does not conflict with the active ingredient (hematopoietic stem cell).

[0048] In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the hematopoietic stem cells.

[0049] In some embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable biomaterial, including but not limited to collagen, gelatin, amino-modified gelatin, chitosan, cellulose, fibrin, polylactic acid, cellulose polylactic acid, polyurethane, tropoelastin, hyaluronic acid, sodium alginate, polyethylene glycol, polylactic acid glycolic acid, polycaprolactone, silicate, silicone rubber, extracellular matrix or any combination thereof, etc. In certain embodiments, the pharmaceutical composition comprises a pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solution (e.g., isotonic saline solution or physiological saline), dispersion, emulsion or suspension.

[0050] In certain embodiments, the pharmaceutical composition can be in any form known in the medical field. For example, the pharmaceutical composition can be in the form of tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (e.g., injections, lyophilized powders), etc. In certain preferred embodiments, the pharmaceutical composition is an injection (including injections, lyophilized powders) or an aerosol.

[0051] Further exemplarily, when the pharmaceutical composition is an injectable preparation, in certain embodiments, the dosage of the mesenchymal stem cells is at least 1×10 5 / mL (e.g. at least 2×10 5 / ml, at least 3×10 5 / ml, at least 5×10 5 / ml, at least 7×10 5 / ml, at least 1×10 6 / ml, at least 3×10 6 / ml, at least 5×10 6 / ml, at least 7×10 6 / ml, at least 1×10 7 / ml, at least 3×10 7 / ml, at least 5×10 7 / ml, at least 7×10 7 / ml, at least 1×10 8 / ml, at least 3×10 8 / ml, at least 5×10 8 / ml, at least 7×10 8 / ml, at least 1×10 9 / ml, at least 3×10 9 / ml, at least 5×10 9 / ml, at least 7×10 9 Pieces / ml.

[0052] In certain embodiments, the subject for which the pharmaceutical composition is directed is a mammal, such as a human.

[0053] In a ninth aspect, the present invention provides a method for treating a disease, comprising administering a pharmaceutical composition comprising the hematopoietic stem cells of the present invention to a subject.

[0054] In some embodiments, the drug is in a unit dosage form, and the unit dosage (e.g., per milliliter) of the drug contains at least 1×10 4 (e.g. at least 1×10 4 At least 3×10 4 At least 5×10 4 At least 7×10 4 At least 1×10 5 At least 3×10 5 At least 5×10 5 At least 7×10 5 At least 1×10 6 At least 3×10 6 At least 5×10 6 At least 7×10 6 At least 1×10 7 At least 3×10 7 At least 5×10 7 At least 7×10 7 At least 1×10 8 At least 3×10 8 At least 5×10 8 At least 7×10 8 At least 1×10 9 At least 3×10 9 At least 5×10 9 At least 7×10 9 At least 1×10 10 At least 3×10 10 At least 5×10 10 or at least 7×10 10 , preferably 3 to 6 × 10 6 ) of the hematopoietic stem cells.

[0055] In certain embodiments, the subject is a mammal, such as a human.

[0056] In certain embodiments, a preventively and / or therapeutically effective amount of hematopoietic stem cells is administered to a subject by injection, mucosal administration, cavity administration, oral administration, respiratory tract administration, or skin administration.

[0057] Beneficial Effects

[0058] The inventors surprisingly found that compared with the mainstream separation methods in the prior art, the hematopoietic stem cells separated and then cultured by the method of the present invention have strong uniformity and high cell viability, which are mainly reflected in the characteristics of fast cell proliferation and high number of passages. Unexpectedly, the addition of sodium selenite and phosphoryl dipeptide increases the recovery rate of hematopoietic stem cells obtained by the method of the present invention and the removal rate of red blood cells. These two compounds may promote the recovery of nucleated cells and CD34 cells by affecting the hematopoietic system.

[0059] Sodium selenite and phosphoryl dipeptide are two different compounds, and the reason why their combination has an effect on the nucleated cell recovery rate and red blood cell removal rate may be related to their mechanism of action in vivo.

[0060] Sodium selenite is a selenium-containing compound. Selenium has an antioxidant effect in the body. It can promote the proliferation and differentiation of hematopoietic stem cells, which may lead to an increase in the recovery rate of nucleated cells and CD34 cells.

[0061] Phospho-dipeptide is a phosphorus-containing compound. Phosphorus is involved in many biochemical processes in cells, including energy metabolism and cell signal transduction. Phospho-dipeptide may affect the function of hematopoietic stem cells by regulating cell metabolism and signal transduction pathways, thereby increasing the recovery rate of nucleated cells and CD34 cells. DETAILED DESCRIPTION

[0062] In order to make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be described in further detail below.

[0063] Example 1

[0064] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0065] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0066] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0067] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0068] The hydroxyethyl starch solution contains 2 μM of phosphoryl dipeptide and 5 μM of sodium selenite.

[0069] Example 2

[0070] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0071] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0072] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0073] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0074] The hydroxyethyl starch solution contains 2 μM phosphoryl dipeptide and 10 μM sodium selenite.

[0075] Example 3

[0076] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0077] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0078] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0079] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0080] The hydroxyethyl starch solution contains 2 μM phosphoryl dipeptide and 15 μM sodium selenite.

[0081] Example 4

[0082] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0083] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0084] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0085] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0086] The hydroxyethyl starch solution contains 2 μM of phosphoryl dipeptide and 20 μM of sodium selenite.

[0087] Example 5

[0088] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0089] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0090] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0091] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0092] The hydroxyethyl starch solution contains 2 μM phosphoryl dipeptide and 50 μM sodium selenite.

[0093] Example 6

[0094] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0095] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0096] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0097] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0098] The hydroxyethyl starch solution contains 3 μM phosphoryl dipeptide and 10 μM sodium selenite.

[0099] Example 7

[0100] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0101] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0102] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0103] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0104] The hydroxyethyl starch solution contains 5 μM phosphoryl dipeptide and 10 μM sodium selenite.

[0105] Example 8

[0106] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0107] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0108] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0109] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0110] The hydroxyethyl starch solution contains 10 μM phosphoryl dipeptide and 10 μM sodium selenite.

[0111] Example 9

[0112] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0113] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0114] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0115] d. Second centrifugation: centrifuge at 400g and 10℃ for 15min to remove plasma.

[0116] The hydroxyethyl starch solution contains 15 μM phosphoryl dipeptide and 10 μM sodium selenite.

[0117] Example 10

[0118] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0119] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0120] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0121] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0122] The hydroxyethyl starch solution contains 20 μM of phosphoryl dipeptide and 10 μM of sodium selenite.

[0123] Comparative Example 1

[0124] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0125] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0126] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0127] d. Second centrifugation: Centrifuge at 400g and 10°C for 15 min to remove plasma and obtain hematopoietic stem cells.

[0128] Comparative Example 2

[0129] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0130] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0131] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0132] d. Second centrifugation: centrifugation at 400 g and 10° C. for 15 min to remove plasma to obtain hematopoietic stem cells, wherein the hydroxyethyl starch solution contains a phosphoryl dipeptide concentration of 2 μM.

[0133] Comparative Example 3

[0134] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0135] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0136] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0137] d. Second centrifugation: centrifugation at 400 g and 10° C. for 15 min to remove plasma to obtain hematopoietic stem cells, wherein the hydroxyethyl starch solution contains a phospholipase dipeptide concentration of 10 μM.

[0138] Comparative Example 4

[0139] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0140] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0141] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0142] d. Second centrifugation: centrifugation at 400 g and 10° C. for 15 min to remove plasma to obtain hematopoietic stem cells, wherein the concentration of sodium selenite is 10 μM.

[0143] Comparative Example 5

[0144] a. Resuscitate the frozen umbilical cord blood and mix 6% hydroxyethyl starch solution and umbilical cord blood in a ratio of 1:5;

[0145] b. Slowly shake the mixture prepared in step a on a shaker for 10 min;

[0146] c. First centrifugation: centrifuge at 50g, 10°C for 7 minutes, and then collect the upper layer of leukocyte-rich plasma;

[0147] d. Second centrifugation: centrifugation at 400 g and 10° C. for 15 min to remove plasma to obtain hematopoietic stem cells, wherein the concentration of sodium selenite is 30 μM.

[0148] The nucleated cells prepared in the above examples were analyzed for nucleated cell recovery rate, CD34 cell recovery rate and red blood cell removal rate, and the results were as follows:

[0149] Analysis results of hematopoietic stem cells derived from umbilical cord blood

[0150] Example Nucleated cell recovery rate (%) CD34 cell recovery rate (%) Red blood cell removal rate (%) Example 1 91.2 95.3 96.8 Example 2 92.6 96.8 97.3 Example 3 91.7 94.5 96.5 Example 4 92.3 96.1 98.1 Example 5 93.7 97.3 96.9 Example 6 93.4 95.2 97.3 Example 7 92.7 94.6 97.1 Example 8 92.1 94.9 97.6 Example 9 91.6 93.2 98.3 Example 10 92.1 94.2 95.9 Comparative Example 1 85.3 88.3 79.5 Comparative Example 2 82.9 83.4 81.2 Comparative Example 3 86.8 82.5 80.4 Comparative Example 4 83.6 81.2 81.1 Comparative Example 5 82.5 83.5 82.6

[0151] It can be seen that the hydroxyethyl starch solution added with a combination of phospholipase dipeptide and sodium selenite can improve the nucleated cell recovery rate, CD34 cell recovery rate and red blood cell removal rate in the separation of hematopoietic stem cells from umbilical cord blood, and is not sensitive to its concentration, and can achieve significantly better results above 2μM.

[0152] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for isolating umbilical cord blood stem cells from umbilical cord blood, comprising the following steps: a. Obtaining umbilical cord blood; b. preparing a hydroxyethyl starch solution and adding sodium selenite and phosphoryl dipeptide to the solution; c. Mixing the hydroxyethyl starch solution added with sodium selenite and phospho-dipeptide with the umbilical cord blood; d. First centrifugation: centrifuge and collect leukocyte-rich plasma; e. Second centrifugation: Centrifuge to remove plasma.

2. The method according to claim 1, wherein the concentration of the sodium selenite is 1 to 100 μM: the concentration of the phosphoryl dipeptide is 0.1 to 50 μM, for example, the concentration of the sodium selenite is 10 to 50 μM, for example, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 the concentration of the phosphodiester is 0.5-30 μM, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 μM.

3. The method according to claim 1 or 2, wherein the concentration of the hydroxyethyl starch solution is 6%.

4. According to the method of claim 1 or 2, the ratio of the hydroxyethyl starch solution to the umbilical cord blood is 1:4 to 1:6, preferably 1:

5.

5. The method according to claim 1 or 2, comprising further culturing the separated hematopoietic stem cells in vitro.

6. Use of sodium selenite and / or phosphoryl dipeptide in the preparation of a kit for separating hematopoietic stem cells from umbilical cord blood.

7. Hydroxyethyl starch solution containing sodium selenite and phosphoryl dipeptide.

8. The solution according to claim 7, wherein the concentration of sodium selenite is 1 to 100 μM: the concentration of the phosphoryl dipeptide is 0.1 to 50 μM, for example, the concentration of sodium selenite is 10 to 50 μM, for example 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 the concentration of the phosphodiester is 0.5-30 μM, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 μM.

9. Use of hematopoietic stem cells separated or cultured by the method according to any one of claims 1 to 5 in the treatment of leukemia or immune diseases.

10. A pharmaceutical composition comprising hematopoietic stem cells separated or cultured by the method according to any one of claims 1 to 5, optionally further comprising a pharmaceutically acceptable carrier or excipient, or other auxiliary materials.

Citation Information

Patent Citations

  • Method for separating nucleated cells from cord blood

    CN104403995A

  • Method for separating hematopoietic stem cells of umbilical cord blood

    CN117866887A

  • Method for separating and culturing umbilical cord-derived mesenchymal stem cells

    CN119120359A

  • A culture medium for hematopoietic stem cells and the applications thereof as well as the stem cells cultire method

    EP3098307A1